阿德福韦酯联合安络化纤丸治疗慢性乙型肝炎肝纤维化临床观察(1)
 |
| 第1页 |
参见附件(1655KB，2页)。
[摘要] 目的：探讨阿德福韦酯联合安络化纤丸治疗慢性乙型肝炎肝纤维化的临床疗效。方法：慢性乙型病毒性肝炎肝纤维化患者共70例，分为治疗组和对照组。对照组35例仅使用阿德福韦酯治疗。治疗组35例在对照组的基础上加用安络化纤丸口服。两组疗程均为48周。结果：所有患者均完成治疗，未出现严重毒副作用，治疗组和对照组治疗前后的相关生化指标都有显著改善(P<0.01)，且治疗组较对照组改善得更为明显(P<0.05)。结论：阿德福韦酯联合安络化纤丸治疗慢性乙型肝炎肝纤维化效果显著。
[关键词] 阿德福韦酯；安络化纤丸；肝纤维化；乙型肝炎
[中图分类号] R512.6+2 [文献标识码] B [文章编号] 1673-7210(2011)12(a)-184-02
Clinical study of Adefovir Dipivoxil combined with Anluohuanxian Pill in the treatment of hepatic fibrosis of chronic hepatitis B patients
DU Jingli, GUO Qingsen*, WU Dezhu, GAO Yuan, ZHI Bobo
Department of Hepatobiliary Surgery, the First Affiliated Hospital of Fuzhou General Hospital, Nanjing Military Command, Fujian Province, Putian 351100, China
[Abstract] Objective: To explore the effect of Adefovir Dipivoxil combined with Anluohuanxian Pill in the treatment of hepatic fibrosis of chronic hepatitis B patients. Methods: 70 patients with chronic hepatitis and liver fibrosis were randomly divided into treatment group and control group. 35 patients in the control group were treated only by Adefovir Dipivoxil. Other 35 patients of treatment group were treated by Anluohuanxian Pill based on the control group. Treatment times of two groups were all 48 weeks. Results: All patients completed the treatment and without any serious side effect. Related biochemical indexes of treatment group and control group were improved significantly before and after treatment (P<0.01), and the related biochemical indexes of treatment group improves more evident than those of the control group (P<0.05). Conclusion: Adefovir Dipivoxil combined with Anluohuanxian Pill have a significant effect in treating hepatic fibrosis of chronic hepatitis B patients.
[Key words] Adefovir Dipivoxil; Anluohuanxian Pill; Liver fibrosis; Hepatitis B
乙型肝炎病毒(HBV)感染已经成为危害全球的疾病，全球60多亿人口中有20亿左右感染，其中25%~40%的患者最终死于肝硬化或肝细胞癌[1]。肝纤维化是患者发生肝硬化早期的病理学基础。研究证实，若能及早有效地治疗，慢性肝炎肝纤维化有逆转的可能[2]。目前在临床上常用中西医结合的方法治疗，笔者2009年6月~2010年12月采用阿德福韦酯联合安络化纤丸治疗该病，疗效满意，现报道如下：
1 资料与方法
1.1 一般资料
选取我院门诊及住院治疗的慢性乙型病毒性肝炎肝纤维化患者70例，分为治疗组和对照组。治疗组35例中，男20例，女15例；年龄25~68岁，平均38.3岁；病程6~32年，平均10.5年。对照组35例中，男22例，女13例；年龄28~65岁 ......
您现在查看是摘要介绍页，详见PDF附件(1655KB，2页)。